Latest Uk Market News

Skellerup Holdings delivered a tenth consecutive year of EBIT growth with a 14% rise to NZD 89.3 million and expanded its climate initiatives, reporting a 24% jump in net profit to NZD 67.7 million.

Doctor Care Anywhere delivered a 27% rise in EBITDA and doubled free cash flow in H1 2026, driven by operational efficiencies and a strategic entry into the UK weight management market via acquisition.

Premier Investments trims FY26 Premier Retail EBIT forecast to $176 million, citing tough trading conditions and announces exit from UK Peter Alexander stores while focusing on Australian growth and loyalty programs.

Kelly Partners Group Holdings boosted FY26 revenue by 18.2% to $159.2 million, underpinned by six acquisitions including a key US CPA firm. Underlying NPATA rose 18.9% to $10.8 million, while the group deepened its global footprint across five countries.

Corporate Travel Management (ASX:CTD) has extended its exclusive contract with the UK Ministry of Defence to provide accommodation services for the Afghan Resettlement Programme, with expected transaction values reaching £28 million in the first six months.

Rua Bioscience has approved a $600,000 convertible note facility aimed at boosting inventory purchases to accelerate its UK market expansion following a major distribution deal.

Nick Scali Limited posted a 31% jump in net profit after tax to $75.7 million for FY26, driven by margin gains and UK sales recovery, and announced a fully franked final dividend of 39 cents per share.

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

Credit Corp delivered a 12% profit rise to a record $105.5 million in FY2026, powered by a 57% surge in US debt buying earnings and a strategic entry into UK consumer lending.

Aspermont Limited reported a 25% year-on-year revenue increase to A$4.5 million in Q3 FY26, achieving normalised EBITDA breakeven for the first time and marking its 40th consecutive quarter of subscription growth. The company’s Data & Intelligence platform advances with key contracts underway and non-subscription revenues surging.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.